FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to use of a combined agent containing an amino nitroxyl complex of platinum BC118, which is e-Ammin-d-(4-amino-2,2,6,6-tetramethylpiperidin-1-oxyl)-a,f-bis(acetate)-b,c-dichloroplatinum (IV), and doxorubicin, as an anticancer agent on model of tumor cells of A-172 and MCF7 lines.
EFFECT: medicinal agent under the invention is effective, allows to reduce toxic load on an organism and severity of by-effects.
1 cl, 2 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT GROWTHS | 2019 |
|
RU2710273C1 |
| COMPOSITION FOR KILLING TNF-α-SENSITIVE TUMOR CELLS | 2002 |
|
RU2209078C1 |
| ANTICANCER TUMOR CISPLATIN COMPOSITION WITH 6-PHOSPHOGLUCONATE DEHYDROGENASE INHIBITOR | 2019 |
|
RU2693004C1 |
| PHARMACEUTICAL COMBINATION FOR TREATMENT AND/OR CHEMOSENSITISATION OF TUMOURS RESISTANT TO ANTICANCER DRUGS | 2007 |
|
RU2396974C2 |
| MONONECLEAR DINITROSYL FERRIC COMPLEXES, METHOD FOR PREPARING MONONECLEAR DINITROSYL FERRIC COMPLEXES, NITROGEN MONOXIDE DONOR, USING MONONECLEAR DINITROSYL FERRIC COMPLEXES AS ANTI-TUMOUR DRUG | 2011 |
|
RU2494104C2 |
| METHYL 6-[(4-(AZIRIDIN-1-YL)-6-CHLORO-1,3,5-TRIAZIN-2-YL)AMINO]HEXANOATE, WHICH HAS A CYTOTOXIC EFFECT | 2022 |
|
RU2791798C1 |
| HUMAN T-LYMPHOBLASTIC LEUCEMIA A4 CELL LINE USEFUL IN SCREENING OF ANTITUMOR AGENTS | 2004 |
|
RU2267532C1 |
| METHOD FOR DIFFERENTIATION STAGE-RELATED HEPATOCARCINOMA CELLS EXPOSURE TO LITHIUM NANOPREPARATIONS | 2014 |
|
RU2560708C1 |
| N-(2-(2-(2-AZIDOETHOXY)ETHOXY)ETHYL)-4,6-DI(AZIRIDIN-1-YL)-1,3,5-TRIAZIN-2-AMINE, HAVING CYTOTOXIC ACTION | 2023 |
|
RU2825828C1 |
| USE OF GOLD POLYACRYLATE AS A HUMAN MELANOMA CELL GROWTH INHIBITOR | 2018 |
|
RU2708626C1 |
